Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis.

Abstract: The technology described herein relates to methods of prognosing and treating bladder cancer.

Abstract: The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis.

Abstract: Disclosed are methods for prognostic evaluation, and diagnosis of cancers. The methods of the present invention allow for the diagnosis and prognosis of cancers by analyzing the levels of expression of an enzyme that is involved in the biosynthetic pathway of spermine within tissue samples containing cancerous tissues. In particular, the amount of enzyme mRNA detected in tissue sample correlates with disease status such that enzyme levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of spermine pathway enzymes in biological samples provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient thus leading to more effective treatments and cures.

Abstract: Disclosed herein is are methods of diagnosing, methods for determining the prognosis for treatment of, and methods for identifying candidate compounds for treating, stabilizing, or preventing cancer, for example, endometrial cancer. These methods utilize the novel tumor suppressor protein, Cables.